EUVIMEDEUVIMED entdecken
Crossref

L26/P-829 Investigating the effect of platelet-rich plasma (PRP) on improving ovarian functionality: Reporting on preclinical data from a NOD/SCID mouse model with chemotherapy-induced diminished ovarian reserve

A. Pantou, K. Pantos, G. Papadogkonas, M. Androutsopoulou, E. Maziotis, A. Trypidi, M. Sakkou, S. Grigoriadis, T. Vaxevanoglou, I. Angeli, P. Tsioulou, K. Sfakianoudis und 1 weitere

Human Reproduction · 01.07.2026 · 41 (Supplement_1)

DOI: 10.1093/humrep/deag083.1156 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Human Reproduction, online erschienen am 08.07.2026. Verfasst von A. Pantou und 12 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Study question Does PRP administration promote ovarian rejuvenation, restore ovarian functionality and improve reproductive outcomes in NOD/SCID mice with chemotherapy-induced diminished ovarian reserve (DOR)? Summary answer PRP does not appear to improve ovarian functionality, albeit reproductive outcomes in DOR NOD/SCID mice are improved. Improved outcomes are achieved strictly post single-dose administration. What is known already Characterized by decreased oocyte count and/or quality, DOR represents a frequent cause of infertility, and a significant challenge to be addressed due to the poor reproductive outcomes. Various novel treatment options have been introduced for the management of DOR patients including intraovarian injection of PRP. Despite conflicting reports, preliminary clinical data indicating that PRP may improve ART success rates by promoting ovarian rejuvenation and restoration of ovarian functionality highlight the need to investigate further. Interestingly, hitherto preclinical data from in-vitro or animal studies are lacking. As the underlying biological mechanisms are still poorly understood, PRP application remains of experimental status. Study design, size, duration This basic-research study, conducted between March-November 2025, employed a NOD/SCID mouse model to evaluate PRP effectiveness at preclinical level. A chemotherapy scheme including 12mg/kg cyclophosphamide along with 1,2mg/kg busulfan was intraperitoneally administered to 9-week old mice inducing DOR, validated by vaginal cytology. Mice were divided into three groups. Group A(n = 12) and group B(n = 12) received a single or double dose of PRP one week apart respectively, while group C(n = 12) received no treatment. Participants/materials, setting, methods Each group (A,B,C) was subdivided into three subgroups. One subgroup was allowed to mate, while the remaining were ovariectomized. The ovaries were used for protein expression analysis. FSHR, LHR, STAR, P450-aromatase, 17β-HSD and VEGF expression were assessed employing Western blot. IGF-1, FGF-2, GDF-9, BMP-15 and VEGF spatial expression were evaluated employing immunohistochemistry. Serum FSH,LH,E2 and,AMH levels were assessed via ELISA. Following ovarian stimulation, oocyte retrieval was performed. Statistical analysis was performed using “R” programming language. Main results and the role of chance Significant differences in FSH(p = 0.004),LH(p < 0.001), and E2(p < 0.001) levels were observed across days. E2(p < 0.001) levels differences were observed among groups. Post-hoc analysis revealed FSH decline between days 1-8(p = 0.013) and days 4-8(p = 0.026). LH increased on day8 compared to day1(p = 0.001), and then decreasing between days 4-12(p = 0.032) and days 8-12(p < 0.001). Ε2 increased between days 1-4(p < 0.001), days 1-8(p < 0.001), and days 1-12(p < 0.001). Higher E2 levels(p < 0.001) were observed in the single-dose versus the double-dose group, especially on day4(p = 0.023). The control group presented with enhanced hormonal recovery compared to the double-dose group(p = 0.029). AMH levels did not differ between groups nor days. Western blot revealed higher FSHR expression in control compared to PRP groups. Lowest and highest expression of aromatase was observed in the double-dose and control group, respectively. No differences between groups were observed regarding LHR,HSD17B1,STAR and VEGF expression. IHC results revealed higher VEGF,IGF-2 and GDF-9 expression in PRP groups compared to control. BMP-15 expression was higher in control compared to PRP groups. A mean of 11.3 Cumulus Oocyte Complexes (COCs) were retrieved per mice in both PRP groups, while no COCs were collected in the control group. Regarding mating results, single-dose PRP mice presented with the higher number of alive pups compared to double-dose PRP and control groups(p = 0.01). Limitations, reasons for caution The small sample size constitutes the main limitation of the current study. Moreover, the fact that human infertility caused by DOR is a multifactorial issue that cannot be fully replicated using animal models is a reason for caution when interpreting the results of the study. Wider implications of the findings Data indicates that while PRP did not improve ovarian functionality, PRP improved reproductive outcomes. Interestingly this was achieved strictly by employing a single-dose administration scheme. PRP effectiveness is dose-dependent in an inverted U-shaped manner. Further research is required prior to definite conclusions regarding the optimal PRP dose in DOR management. Trial registration number No

Zitieren

APA

Pantou, A., Pantos, K., Papadogkonas, G., Androutsopoulou, M., Maziotis, E., Trypidi, A., Sakkou, M., Grigoriadis, S., Vaxevanoglou, T., Angeli, I., Tsioulou, P., Sfakianoudis, K., & Simopoulou, M. (2026). L26/P-829 Investigating the effect of platelet-rich plasma (PRP) on improving ovarian functionality: Reporting on preclinical data from a NOD/SCID mouse model with chemotherapy-induced diminished ovarian reserve. Human Reproduction, 41(Supplement_1). https://doi.org/10.1093/humrep/deag083.1156

Vancouver

Pantou A, Pantos K, Papadogkonas G, Androutsopoulou M, Maziotis E, Trypidi A, et al. L26/P-829 Investigating the effect of platelet-rich plasma (PRP) on improving ovarian functionality: Reporting on preclinical data from a NOD/SCID mouse model with chemotherapy-induced diminished ovarian reserve. Human Reproduction. 2026;41(Supplement_1). doi:10.1093/humrep/deag083.1156

BibTeX
@article{Pantou2026,
  author = {Pantou, A. and Pantos, K. and Papadogkonas, G. and Androutsopoulou, M. and Maziotis, E. and Trypidi, A. and Sakkou, M. and Grigoriadis, S. and Vaxevanoglou, T. and Angeli, I. and Tsioulou, P. and Sfakianoudis, K. and Simopoulou, M.},
  title = {L26/P-829 Investigating the effect of platelet-rich plasma (PRP) on improving ovarian functionality: Reporting on preclinical data from a NOD/SCID mouse model with chemotherapy-induced diminished ovarian reserve},
  journal = {Human Reproduction},
  year = {2026},
  volume = {41},
  number = {Supplement_1},
  doi = {10.1093/humrep/deag083.1156}
}
Kostenlos starten →